American Journal of Cardiology
Volume 104, Issue 2 , Pages 234-239 , 15 July 2009

Long-Term Lipid Effects of Pioglitazone by Baseline Anti-Hyperglycemia Medication Therapy and Statin Use from the PROactive Experience (PROactive 14)

  • Robert Spanheimer, MD

      Affiliations

    • Takeda Pharmaceuticals North America, Inc., Deerfield, Illinois
    • Corresponding Author InformationCorresponding author: Tel: 224-554-6261; fax: 224-554-7842
    • ,
  • D. John Betteridge, MD

      Affiliations

    • University College Hospital, London, United Kingdom
    • ,
  • Meng H. Tan, MD

      Affiliations

    • Eli Lilly & Company, Indianapolis, Indiana
    • ,
  • Ele Ferrannini, MD

      Affiliations

    • Department of Internal Medicine, University of Pisa School of Medicine, Pisa, Italy
    • ,
  • Bernard Charbonnel, MD

      Affiliations

    • University Hospital, Nantes, France
    • ,
  • PROactive Investigators

      Affiliations

    • Conflicts of interest: Drs. Betteridge, Tan, and Charbonnel have served on advisory boards, received grant support, and/or received honoraria for consulting services from Takeda Pharmaceutical Company. Dr. Ferrannini served as an external consultant to the PROactive Steering Committee for 2007 and 2008. Dr. Spanheimer is an employee of Takeda Pharmaceuticals North America. Dr. Tan was an employee of Eli Lilly & Company when the PROactive study was conducted.

Received 17 November 2008 ,Revised 8 March 2009 ,Accepted 8 March 2009.

  • Image Result

    Time course of TG and HDL cholesterol (HDL-C) levels for all patients by baseline antihyperglycemia medication use. * p value for treatment group comparison (pioglitazone vs placebo) <0.01 for each co

    Time course of TG and HDL cholesterol (HDL-C) levels for all patients by baseline antihyperglycemia medication use. * p value for treatment group comparison (pioglitazone vs placebo) <0.01 for each cohort; † p <0.05 for each cohort; ‡ p <0.0001 for each cohort. For all patients (black diamonds), p <0.0001 at all time points for TGs and HDL cholesterol. MET = metformin; SU = sulfonylurea.

  • Image Result
    Time course of TG and HDL cholesterol (HDL-C) levels by baseline statin use. * p value for the treatment group comparison (pioglitazone vs placebo) <0.0001 for the 2 cohorts.

    Time course of TG and HDL cholesterol (HDL-C) levels by baseline statin use. * p value for the treatment group comparison (pioglitazone vs placebo) <0.0001 for the 2 cohorts.

 This study is registered as an International Standard Randomized Controlled Trial (NCT00174993) and was funded by Takeda Pharmaceutical Company, Deerfield, Illinois, and Eli Lilly & Company, Indianapolis, Indiana.

PII: S0002-9149(09)00733-4

doi: 10.1016/j.amjcard.2009.03.023

American Journal of Cardiology
Volume 104, Issue 2 , Pages 234-239 , 15 July 2009

Article Tools

* Image Usage & Resolution